Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 3/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526503 | 0.79 | ALOX15 (0.35) | MAOAMAOBALOX5AHR | |
| Arsenic SCHEMBL28557236 | 0.77 | — | — | |
| SCHEMBL3102452 | 0.73 | MAOA (0.56) | MAOAMAOBALOX5AHRABCG2 | |
| SCHEMBL29383458 | 0.73 | MAOA (0.56) | MAOAMAOBALOX5AHRABCG2 | |
| SCHEMBL4571011 | 0.73 | MAOA (0.56) | MAOAMAOBALOX5AHRABCG2 | |
| SCHEMBL8668546 | 0.73 | MAOA (0.56) | MAOAMAOBALOX5AHRABCG2 | |
| SCHEMBL205284 | 0.73 | — | — | |
| SCHEMBL8776016 | 0.73 | CYP2A6 (0.36) | KDM4EALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL125113 | 0.73 | MAOA (0.56) | MAOAMAOBALOX5AHRABCG2 | |
| SCHEMBL29724179 | 0.73 | MAOA (0.56) | MAOAMAOBALOX5AHRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024143358-A1 | RECYCLED POLYCARBONATE RESIN AND METHOD FOR PRODUCING SAME | 三菱ケミカル株式会社 | 2024-07-04 | — | — | WO | claimed |
| EP-4380998-A2 | METHOD OF SYNTHESIZING A MUCIN AND PRODUCT THEREOF | Research Foundation Of The City University Of New York (US) | 2024-06-12 | — | — | EP | claimed |
| US-20240182950-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING PHOSPHOSERINE-CONTAINING POLYPEPTIDES | Quantum-Si Incorporated (US) | 2024-06-06 | — | — | US | claimed |
| WO-2024086781-A2 | METHODS AND SYSTEMS FOR CHARACTERIZING PHOSPHOSERINE-CONTAINING POLYPEPTIDES | Quantum-Si Incorporated (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2023210563-A1 | COMPOSITION CONTAINING BISPHENOL, PRODUCTION METHOD FOR SAME, PRODUCTION METHOD FOR BISPHENOL A, AND PRODUCTION METHOD FOR POLYCARBONATE RESIN | 三菱ケミカル株式会社 | 2023-11-02 | — | — | WO | claimed |
| WO-2023014875-A2 | METHOD OF SYNTHESIZING A MUCIN AND PRODUCT THEREOF | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2023-02-09 | — | — | WO | claimed |
| EP-3262058-A1 | A COMPOUND FOR PREPARING POLYPEPTIDES | Universität Wien (AT) | 2018-01-03 | — | — | EP | claimed |
| WO-2016135071-A1 | A COMPOUND FOR PREPARING POLYPEPTIDES | Universität Wien (AT) | 2016-09-01 | — | — | WO | claimed |
| US-20140171455-A1 | Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-19 | — | — | US | claimed |
| EP-2717871-A2 | REDUCTION OF MICROGLIA-MEDIATED NEUROTOXICITY BY KV1.3 INHIBITION | The Regents of the University of California (US) | 2014-04-16 | — | — | EP | claimed |
| WO-2006048225-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | claimed |
| EP-1569899-A2 | SUBSTITUTED 3-ALKYL AND 3-ARYLALKYL i 1H /i -INDOL-1-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004052853-A2 | SUBSTITUTED 3-ALKYL AND 3-ARYLALKYL 1H-INDOL-1-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | claimed |
| US-20040116488-A1 | Substituted 3-alkyl and 3-arylalkyl 1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2004-06-17 | — | — | US | claimed |
| US-5707559-A | PROVIDING A STABLE 1,2-DIOXETANE WHICH FORMS INTERMEDIATE UNSTABLE COMPOUNDS WHEN TRIGGERED TO REMOVE BLOCKING GROUPS BY ACTIVATING AGENT SO THAT UNSTABLE COMPOUND DECOMPOSES TO FORM LIGHT AND TWO CARBONYL COMPOUNDS | TROPIX, INC. (US) | 1998-01-13 | — | — | US | claimed |
| US-5332857-A | 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents | PFIZER INC. (US) | 1994-07-26 | — | — | US | claimed |
| EP-0312269-B1 | 3,5-DIHYDROXY-6,8-NONADIENOIC ACIDS AND DERIVATIVES AS HYPOCHOLESTEROLEMIC AGENTS | PFIZER INC. (US) | 1993-06-16 | — | — | EP | claimed |
| US-4877779-A | CALCIUM CHANNEL BLOCKERS; TREATMENT OF IRRITABLE BOWEL SYNDROME | MARION LABORATORIES, INC. (US) | 1989-10-31 | — | — | US | claimed |
| WO-1989003212-A1 | 3,5-DIHYDROXY-6,8-NONADIENOIC ACIDS AND DERIVATIVES AS HYPOCHOLESTEROLEMIC AGENTS | PFIZER INC. (US) | 1989-04-20 | — | — | WO | claimed |
| EP-0312269-A2 | 3,5-Dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents | PFIZER INC. (US) | 1989-04-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171455-A1 | Reduction of Microglia-Mediated Neurotoxicity by Kv1.3 Inhibition | KCNMA1, KCNN1, KCNN3 | MAOA 657/4885MAOB 1516/4885ALOX5 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.